Search reports, ask a question, or jump to a page.
The problem
Intervention: BNT162b2 (Pfizer) COVID-19 vaccination with two or three doses
Who it was tested with: 86 adolescents aged 12-17 years with juvenile IMIDs (including SLE and JIA), compared with 37 adult controls under 40 years.
Children or communities are compared with a group that did not receive the intervention, or followed over years. This is the design that best separates what the intervention did from everything else that changed.
"The Brazilian multicenter longitudinal SAFER-Study evaluates immunogenicity and safety of the BNT162b2/Pfizer vaccine in IMID patients." This is a prospective longitudinal design with measurement of safety outcomes (adverse events) and immunogenicity outcomes (antibody responses and seroconversion rates) in a vulnerable pediatric population, meeting criteria for experimental evidence tier.
The study lacks a longer follow-up period to assess durability of immune response and late adverse events. Comparison is made to a limited adult control group rather than to the general pediatric population.
Across countries and designs
8 studies · 5 countries
Classified by the Hub's AI
Not yet reviewed by a person. Model output is not AICS's view until reviewed.
claude-haiku-4-5-20251001 · synth-v1
